| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2008.19.6386 |
| P698 | PubMed publication ID | 19255320 |
| P50 | author | Laurie E. Gaspar | Q100728309 |
| Tracey E. Schefter | Q121436632 | ||
| P2093 | author name string | Stuart H Burri | |
| Brian D Kavanagh | |||
| Thomas J Pugh | |||
| Kyle E Rusthoven | |||
| Changhu Chen | |||
| Madeleine Kane | |||
| Higinia Cardenes | |||
| Mark A Chidel | |||
| P433 | issue | 10 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 1579-1584 | |
| P577 | publication date | 2009-03-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases | |
| P478 | volume | 27 |
| Q89647107 | A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups |
| Q41645384 | A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer |
| Q57282826 | A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer |
| Q101558791 | A multi-institutional phase 2 trial of stereotactic body radiotherapy in the treatment of bone metastases in pediatric and young adult patients with sarcoma |
| Q36388365 | A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases |
| Q89585452 | A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases |
| Q29248448 | A treatment-planning comparison of three beam arrangement strategies for stereotactic body radiation therapy for centrally located lung tumors using volumetric-modulated arc therapy |
| Q54966222 | Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence. |
| Q37617830 | Carbon ion radiotherapy for oligo-recurrent lung metastases from colorectal cancer: a feasibility study |
| Q53701730 | Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. |
| Q52591818 | Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. |
| Q39749392 | Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). |
| Q36304180 | Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer |
| Q30570350 | Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. |
| Q47103518 | Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases |
| Q49356303 | Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases |
| Q35290324 | Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases |
| Q36101987 | Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence |
| Q34202715 | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
| Q37060393 | Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis |
| Q38245873 | Combination of stereotactic ablative body radiation with targeted therapies |
| Q55235684 | Combining radiation plus immunotherapy to improve systemic immune response. |
| Q44946517 | Commissioning and initial stereotactic ablative radiotherapy experience with Vero |
| Q30404155 | Comparative analysis of thermoplastic masks versus vacuum cushions in stereotactic body radiotherapy |
| Q40835700 | Comparison of Clinical Outcomes of VATS and SBRT in the Treatment of NSCLC |
| Q35121736 | Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer |
| Q36112410 | Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study |
| Q35117298 | Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. |
| Q42116312 | Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response |
| Q53045959 | Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. |
| Q35947797 | Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer |
| Q57059398 | Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: A single-center study |
| Q35782954 | Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection |
| Q38786508 | Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases |
| Q35976055 | Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer |
| Q37876669 | Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy |
| Q36550512 | Dosimetric effects of roll rotational setup errors on lung stereotactic ablative radiotherapy using volumetric modulated arc therapy |
| Q64951497 | Efficacy and tolerability of stereotactic body radiotherapy for lung metastases in three patients with pediatric malignancies. |
| Q27015651 | Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice |
| Q61450341 | Evaluation of plan quality and treatment efficiency for single-isocenter/two-lesion lung stereotactic body radiation therapy |
| Q64990381 | Evidence for surgical resections in oligometastatic lung cancer. |
| Q37392508 | Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors |
| Q37151785 | Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree |
| Q43833349 | Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy |
| Q92102154 | Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients |
| Q34806851 | Futility versus utility of marrow assessment in initial Ewing sarcoma staging workup |
| Q46160844 | Future cancer research priorities in the USA: a Lancet Oncology Commission |
| Q49244538 | Helical Therapy is Safe for Lung Stereotactic Body Radiation Therapy Despite Limitations in Achieving Sharp Dose Gradients |
| Q55398195 | Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. |
| Q47141026 | Institutional experience on the treatment of lung and liver lesions with stereotactic body radiotherapy and Novalis Exactrac Adaptive Gating technique |
| Q38880324 | Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer |
| Q59133181 | Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors |
| Q41374649 | Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case |
| Q90579412 | Local ablative radiotherapy for oligometastatic non-small cell lung cancer |
| Q40395624 | Local ablative radiotherapy of oligometastatic colorectal cancer |
| Q89622211 | Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain |
| Q37670425 | Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung |
| Q90024663 | Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer |
| Q41710571 | Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT). |
| Q47098433 | Lung reirradiation with stereotactic body radiotherapy |
| Q47121935 | Lung reirradiation with stereotactic body radiotherapy (SBRT). |
| Q47102090 | Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam technique: a comparison of clinical outcomes |
| Q37117211 | Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases |
| Q38945542 | Management of Sarcoma Metastases to the Lung |
| Q102141797 | Metastasis-directed therapy for oligometastasis and beyond |
| Q27311314 | MicroRNA expression characterizes oligometastasis(es) |
| Q26849767 | Minimally invasive local treatments for bone and pulmonary metastases |
| Q64982401 | Moving targets in 4D-CTs versus MIP and AIP: comparison of patients data to phantom data. |
| Q35854741 | Multicentre results of stereotactic body radiotherapy for secondary liver tumours |
| Q38042427 | Novel insights of oligometastases and oligo-recurrence and review of the literature |
| Q27334649 | Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs |
| Q37667254 | Oligometastases and oligo-recurrence: the new era of cancer therapy |
| Q37725741 | Oligometastases confined one organ from colorectal cancer treated by SBRT. |
| Q56773912 | Oligometastases revisited |
| Q38091331 | Oligometastases: the new paradigm and options for radiotherapy. A critical review |
| Q26828767 | Oligometastasis and oligo-recurrence: more than a mirage |
| Q39371168 | Oligometastatic Disease in Pancreatic Cancer - How to Proceed? |
| Q42157461 | Oligometastatic disease, the curative challenge in radiation oncology |
| Q37643566 | Oligometastatic non-small-cell lung cancer: current treatment strategies |
| Q41632731 | Oligoprogression |
| Q33826696 | Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors |
| Q38907646 | PD-1 Restrains Radiotherapy-Induced Abscopal Effect. |
| Q34123571 | Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors |
| Q30426369 | Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review |
| Q35111775 | Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer |
| Q28727917 | Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases |
| Q35036765 | Pneumomediastinum as a complication of SABR for lung metastases |
| Q64072724 | Potential reduction of lung dose via VMAT with jaw tracking in the treatment of single-isocenter/two-lesion lung SBRT |
| Q33875793 | Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy |
| Q36448069 | Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy |
| Q90264673 | Prognostic factors in stereotactic body radiotherapy of lung metastases |
| Q61813248 | Proton beam therapy is a safe and feasible treatment for patients with second primary lung cancer after lung resection |
| Q37791027 | Pulmonary metastasis: rationale for local treatments and techniques. |
| Q99582912 | Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience |
| Q30416741 | Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary |
| Q47142130 | Quality and safety in stereotactic radiosurgery and stereotactic body radiation therapy: can more be done? |
| Q47153259 | Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model. |
| Q41487973 | Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future |
| Q38256158 | Radiation pneumonitis after stereotactic radiation therapy for lung cancer |
| Q36340608 | Radiation therapy for cutaneous melanoma |
| Q34124296 | Radical irradiation of extracranial oligometastases |
| Q38685466 | Radiobiology of stereotactic body radiation therapy (SBRT). |
| Q26738443 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice |
| Q42109226 | Radiotherapy for Oligometastatic Lung Cancer |
| Q26864247 | Review and uses of stereotactic body radiation therapy for oligometastases |
| Q50529485 | Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. |
| Q61813694 | Role of radiotherapy in the treatment of metastatic head and neck cancer |
| Q37708013 | Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer |
| Q98157769 | SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges |
| Q40179018 | SBRT for lung oligometastases: Who is the perfect candidate? |
| Q37254116 | Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma |
| Q57296865 | Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression |
| Q38871523 | Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies |
| Q64094411 | Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases |
| Q64229928 | Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury |
| Q38904089 | Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors |
| Q34196471 | Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach |
| Q57020608 | Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience |
| Q52592765 | Stereotactic Body Radiation Therapy for Pulmonary Oligometastases Arising from Non-lung Primaries in Patients Without Extrapulmonary Disease. |
| Q64248763 | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series |
| Q47140283 | Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control |
| Q36286591 | Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours |
| Q39051290 | Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer |
| Q85411319 | Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases |
| Q31075401 | Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial |
| Q37348287 | Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. |
| Q100573253 | Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers |
| Q90478112 | Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? |
| Q57987901 | Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization |
| Q88640211 | Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT |
| Q42159558 | Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control |
| Q34304095 | Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects |
| Q39373725 | Stereotactic body radiation therapy for primary and metastatic liver tumors |
| Q37649474 | Stereotactic body radiation therapy: a novel treatment modality |
| Q33782847 | Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology. |
| Q37723610 | Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments |
| Q50851277 | Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience. |
| Q35646076 | Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry |
| Q38059705 | Stereotactic body radiotherapy for metachronous multisite oligo-recurrence: a long-surviving case with sequential oligo-recurrence in four different organs treated using locally radical radiotherapy and a review of the literature |
| Q36321076 | Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases |
| Q45170619 | Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease |
| Q37152196 | Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions. |
| Q47105170 | Stereotactic body radiotherapy for primary and metastatic liver tumors - the Mayo Clinic experience |
| Q86157828 | Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events |
| Q93069239 | Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer |
| Q38046079 | Stereotactic body radiotherapy treatment of extracranial metastases |
| Q38175120 | Stereotactic body radiotherapy: a critical review for nonradiation oncologists |
| Q28076058 | Stereotactic body radiotherapy: current strategies and future development |
| Q34163370 | Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib |
| Q26796675 | Strategies for combining immunotherapy with radiation for anticancer therapy |
| Q52582229 | Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung c |
| Q92372917 | Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? |
| Q37801046 | Surgical and Nonresectional Therapies for Pulmonary Metastasis |
| Q38808780 | Systemic Versus Local Therapies for Colorectal Cancer Pulmonary Metastasis: What to Choose and When? |
| Q92129620 | The case for radiotherapy in a Value based environment |
| Q57172942 | The current state of oligometastatic and oligoprogressive non-small cell lung cancer |
| Q64099116 | The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases |
| Q46288612 | The oligometastatic state - separating truth from wishful thinking |
| Q37878852 | The role of local therapy in the management of lung and liver oligometastases. |
| Q35113011 | The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms |
| Q38214799 | The role of stereotactic radiotherapy in the treatment of oligometastases |
| Q89906033 | The short-term outcomes of pulmonary metastasectomy or stereotactic body radiation therapy for pulmonary metastasis from epithelial tumors |
| Q36835347 | Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). |
| Q39371182 | Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer |
| Q64973779 | Treatment for non-small-cell lung cancer and circulating tumor cells. |
| Q55350018 | Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy. |
| Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
Search more.